Immunovant, Inc. (IMVT)

Immunovant Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	May 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Market Cap	7,011	5,066	2,907	4,704	2,021	642
Market Cap Growth	188.65%	74.25%	-38.19%	132.70%	214.95%	-59.16%
Enterprise Value	6,109	4,164	2,193	4,068	1,645	149.22
Last Close Price	34.15	24.84	17.09	32.31	15.51	5.51
PB Ratio	8.17	5.94	4.11	7.61	5.58	1.37
P/TBV Ratio	7.31	5.32	3.66	7.22	5.27	1.29
Debt / Equity Ratio	-	0	0	0	0.00	0.00
Net Debt / Equity Ratio	-1.06	-1.06	-1.01	-1.03	-1.03	-1.05
Net Debt / EBITDA Ratio	1.69	1.69	1.63	2.25	1.72	3.15
Net Debt / FCF Ratio	2.22	2.22	1.90	2.96	1.99	4.62
Quick Ratio	8.65	8.65	10.41	13.18	8.71	11.37
Current Ratio	9.09	9.09	11.16	13.70	9.34	11.52
Return on Equity (ROE)	-55.00%	-64.82%	-62.46%	-52.91%	-50.69%	-36.39%
Return on Assets (ROA)	-53.06%	-61.52%	-60.88%	-52.85%	-47.38%	-33.61%
Return on Invested Capital (ROIC)	1849.18%	1923.82%	3719.90%	1893.72%	1286.87%	1167.90%
Return on Capital Employed (ROCE)	-57.96%	-68.32%	-66.13%	-57.68%	-52.37%	-36.09%
Buyback Yield / Dilution	-20.35%	-20.35%	-9.76%	-12.21%	-12.21%	-24.98%
Total Shareholder Return	-20.35%	-20.35%	-9.76%	-12.21%	-12.21%	-24.98%

Updated May 20, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q